Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
collection:"CTG"
topic_facet:"Phase: Phase 1, Phase 2"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=collection%3A%22CTG%22&filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+1%2C+Phase+2%22&lookfor=%22Myeloma%22&type=Subject
/vufind/Search/Results?filter%5B%5D=collection%3A%22CTG%22&filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+1%2C+Phase+2%22&lookfor=%22Myeloma%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=collection%3A%22CTG%22&filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+1%2C+Phase+2%22&lookfor=%22Myeloma%22&type=Subject
PubPharm (234)
1
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation : A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
2
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment : Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
3
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma : A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Lmmunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Relapsed or Refractory Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
4
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma : An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
5
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma : An Open Label, International, Multicenter, Dose Escalating Phase I/II Trial Investigating the Safety of Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
6
A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma : A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
7
A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma : A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
8
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies : A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
9
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies : A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects With Hematologic Malignancies
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
10
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma : A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[24]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Filter aufheben
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Thema: Phase: Phase 1, Phase 2
Medienart
234
Aufsätze
234
E-Artikel
234
E-Ressourcen
Zeitschriftentitel
234
ClinicalTrials.gov
Thema
234
610
234
Multiple Myeloma
Phase: Phase 1, Phase 2
234
Study Type: Interventional
213
Neoplasms, Plasma Cell
87
Recruitment Status: Recruiting
55
Recruitment Status: Active, not recruiting
44
Recruitment Status: Completed
24
Recruitment Status: Terminated
19
Medical Condition: Multiple Myeloma
16
Lymphoma
13
Recruitment Status: Not yet recruiting
12
Hematologic Neoplasms
9
Myelodysplastic Syndromes
9
Neoplasms
7
Leukemia
7
Recruitment Status: Withdrawn
6
Leukemia, Myeloid, Acute
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Lymphoma, Non-Hodgkin
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
95
2024
102
2023
23
2022
14
2021
Erscheinungsjahr(e)
Von:
Bis:
Sprache
234
Englisch
Haven't found what you're looking for?
Wird geladen...